The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | Key takeaways from ASH 2020 in multiple myeloma
Thomas Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, explores key takeaways from the recent ASH 2020 virtual meeting, including progression-free survival data using daratumumab, lenalidomide, and dexamethasone combination therapy in transplant ineligible patients with multiple myeloma, as well as results of the FORTE trial (NCT02203643) presented at ASH. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.
